DelveInsight’s “Ascites Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Ascites pipeline landscapes. It comprises Ascites pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Ascites therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Ascites pipeline products.
Some of the key takeaways of the Ascites Pipeline Report
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such asGrifols S.A., BioVie Inc., Noorik Biopharmaceuticals, Clover Biopharmaceuticals, etc., are developing therapies for the treatment of Ascites.
Emerging therapies such as Albutein 20% Injectable Solution, BIV201, N-003, SCB-313, are expected to have a significant impact on the Ascites market in the coming years.
The growing incidence of Ascites is predicted to drive the expansion of the Ascites market.
The rise in the prevalence of cirrhosis and alcohol consumption is anticipated to drive the Ascites market.
Get an overview of pipeline landscape @ Ascites Clinical Trials Analysis
When over 25 millilitres (mL) of fluid builds up inside the abdomen, it’s referred to as ascites. Ascites usually occur when the liver stops working properly. When the liver malfunctions, fluid fills the space between the abdominal lining and therefore the organs.
Cirrhosis of the liver is the most typical reason behind ascites, but other conditions like heart failure, kidney failure, infection, or cancer also can cause the disease. Ascites are caused by a mixture of elevated pressure within the veins running through the liver (portal hypertension) and a decrease in liver function caused by scarring of the liver, i.e., cirrhosis.
Ascites Emerging Drugs
Albutein 20% Injectable Solution by Grifols S.A.
BIV201 by BioVie Inc.
N-003 by Noorik Biopharmaceuticals
SCB-313 by Clover Biopharmaceuticals
And others.
Scope of Ascites Pipeline Drug Insight
Coverage: Global
Major Players:Grifols S.A., BioVie Inc., Noorik Biopharmaceuticals, Clover Biopharmaceuticals, and others.
Pipeline Therapies: Albutein 20% Injectable Solution, BIV201, N-003, SCB-313, and others.
Table of Contents
1
Ascites Report Introduction
2
Ascites Executive Summary
3
Ascites Overview
4
Ascites- Analytical Perspective In-depth Commercial Assessment
5
Ascites Pipeline Therapeutics
6
Ascites Late Stage Products (Phase II/III)
7
Ascites Mid Stage Products (Phase II)
8
Ascites Early Stage Products (Phase I)
9
Ascites Preclinical Stage Products
10
Ascites Therapeutics Assessment
11
Ascites Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Ascites Key Companies
14
Ascites Key Products
15
Ascites Unmet Needs
16
Ascites Market Drivers and Barriers
17
Ascites Future Perspectives and Conclusion
18
Ascites Analyst Views
19
Appendix
20
About DelveInsight
Related Reports:
Ascites Market
DelveInsight’s Ascites – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Ascites, historical and forecasted epidemiology as well as the Ascites market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Ascites Epidemiology
DelveInsight’s ‘ Ascites- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Ascites epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/